AstraZeneca (AZN)

Executive Summary

AstraZeneca (AZN) is a global biopharmaceutical leader with a market cap of ~$293B, driven by a diversified portfolio spanning oncology, cardiovascular/renal/metabolic (CVRM), respiratory & immunology, vaccines, and rare disease. The company boasts 16 blockbuster medicines and a robust pipeline of 197 projects, leveraging advanced genomics, AI-driven drug discovery, and next-generation therapeutics. Key commercial assets include Tagrisso, Imfinzi, Lynparza, and Farxiga, which continue to generate strong revenue growth. Recent approvals such as Enhertu in breast cancer and the RSV antibody Beyfortus have further strengthened its position. With a focus on precision medicine and early-stage lung cancer, AstraZeneca is well-positioned to sustain long-term growth. The company’s commitment to R&D, evidenced by a 23% R&D-to-sales ratio, supports a rich pipeline of potential blockbusters across high-unmet-need areas. Upcoming catalysts include regulatory decisions for datopotamab deruxtecan (Dato-DXd) in HR+/HER2- breast cancer, Phase 3 readouts for capivasertib in prostate cancer, and potential label expansions for Imfinzi in early-stage non-small cell lung cancer. These events could drive significant value and reinforce AstraZeneca’s leadership in oncology. Despite macro headwinds, the company’s diversified revenue streams and late-stage pipeline provide resilience. With a conviction score of 85, AstraZeneca represents a high-quality investment opportunity in the biopharma sector.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on datopotamab deruxtecan (Dato-DXd) for HR+/HER2- breast cancer60% success
• Q4 2026Phase 3 data readout for capivasertib in metastatic castration-resistant prostate cancer50% success
• Q2 2026Regulatory submission for Imfinzi (durvalumab) in early-stage NSCLC following PACIFIC-2 update70% success